FRC
FRC Logo
CommunityMarkets
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileGilead Sciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GILD
Gilead Sciences, Inc. Stock AnalysisComprehensive stock analysis for Gilead Sciences, Inc. (GILD) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisGILD
GILD
Gilead Sciences, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
GILD
  1. Home
  2. Stocks
  3. Gilead Sciences, Inc.

Gilead Sciences, Inc.

🇺🇸GILD•NASDAQ

Gilead Sciences, Inc.

🇺🇸GILD•NASDAQ
Market cap
$207.86B
Sentiment

Your view on GILD

Mkt Cap
$207.86B
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Gilead Sciences, Inc.

Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Daniel P. O'Day
Headquarters
333 Lakeside Drive, Foster City, CA, US
Industry
Drug Manufacturers - General
Sector
Healthcare
CEO
Daniel P. O'Day
Headquarters
333 Lakeside Drive, Foster City, CA, US
Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.

; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Gilead Sciences, Inc. from FRC's valuation model, read against the market price. GILD last traded at $167.58; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Gilead Sciences, Inc.. Starting points for Gilead Sciences, Inc.: EPS -$3.11, beta 0.36 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Gilead Sciences, Inc.. Gilead Sciences, Inc. paid $3.25 per share over the last year — a 1.9% yield at the current $167.58 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Gilead Sciences, Inc.. Trailing twelve-month EPS for Gilead Sciences, Inc. stands at -$3.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$165.83

average of 23 firms, last 12 months

 

$165.83

Low $126.00

Median $165.00

High $196.00

 

Analyst Ratings

Buy16 firms, last 12 months
  • Strong Buy0
  • Buy13
  • Hold3
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$1.24$2.14-$0.95$10.15
Low estimate$1.05$2.06-$1.31$9.46
High estimate$1.42$2.21-$0.34$12.46
No. of analysts1341616
Year-ago EPS$1.86$2.03$6.78—
Growth-33.4%+5.4%-114.0%—

Revenue Estimate

RevenueCurrent QtrDec 2026Next QtrMar 2027Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$8.30B$7.47B$31.34B$33.56B
Low estimate$8.22B$7.37B$30.75B$32.39B
High estimate$8.39B$7.58B$31.54B$34.17B
No. of analysts1131819
Year-ago revenue$7.92B$6.96B$29.44B—
Growth+4.7%+7.4%+6.5%—
Recent analyst actions15 rating and price-target changes, latest Nov 18, 2026 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Gilead Sciences, Inc.. Gilead Sciences, Inc. has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold GILD18 companies · 8 funds
Compare GILD with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ABBVAbbVie Inc.Drug Manufacturers - General$520.9B
  • AZNAstraZeneca PLCDrug Manufacturers - General$285.4B
  • GSKGSK plcDrug Manufacturers - General$101.3B
  • JNJJohnson & JohnsonDrug Manufacturers - General$687.9B
  • LLYEli Lilly and CompanyDrug Manufacturers - General$1.3T
  • MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
  • NVSNovartis AGDrug Manufacturers - General$302.6B
  • PFEPfizer Inc.Drug Manufacturers - General$164.5B

More Drug Manufacturers - General companies

  • ALPMFAstellas Pharma Inc.OTC$28.1B
  • ALPMYAstellas Pharma Inc.OTC$29.2B
  • AMGNAmgen Inc.NASDAQ$250.1B
  • AMRNAmarin Corporation plcNASDAQ$234M
  • BAYRYBayer AGOTC$49.0B
  • BIIBBiogen Inc.NASDAQ$37.2B
  • BMYBristol-Myers Squibb CompanyNYSE$128.6B
  • CHGCFChugai Pharmaceutical Co., Ltd.OTC$105.3B
  • CHGCYChugai Pharmaceutical Co., Ltd.OTC$110.0B
  • CHJTFCSPC Pharmaceutical Group LimitedOTC$15.8B

ETFs holding Gilead Sciences, Inc.

% of the fund

  • VOOVanguard S&P 500 ETF$1.0T in assets0.32%
  • VTIVanguard Total Stock Market ETF$689.2B in assets0.29%
  • QQQInvesco QQQ Trust, Series 1$446.1B in assets1.00%
  • IVViShares Core SP 500 ETF$852.9B in assets0.33%
  • BBHVanEck Biotech ETF$536M in assets14.81%
  • IBBiShares Biotechnology ETF$11.1B in assets9.38%
  • FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.74%
  • IYHiShares US Healthcare ETF$4.7B in assets3.08%

Largest holders first, then the funds most concentrated in GILD.

Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Gilead Sciences, Inc., and how their positions are changing. At a $207.86B market value, institutional positions materially move Gilead Sciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Gilead Sciences, Inc. executives and directors. Shares of Gilead Sciences, Inc. have traded between $87.77 and $127.68 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

About this section

U.S. Senate disclosures naming Gilead Sciences, Inc.. Gilead Sciences, Inc. is a $207.86B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.

House Trading

U.S. Representative disclosures filed under the STOCK Act.

About this section

U.S. House of Representatives disclosures naming Gilead Sciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Gilead Sciences, Inc.. Coverage tracks Gilead Sciences, Inc. within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Gilead Sciences, Inc.

GILD Analysis
Good
Past3
Growth2
Health5
Profit5
Value1

News

Latest Market News